Investing.com - Caribou Biosciences (NASDAQ: CRBU) reported first quarter EPS of $-0.460, $0.06 worse than the analyst estimate of $-0.400. Revenue for the quarter came in at $2.43M versus the consensus estimate of $2.9M.
Caribou Biosciences's stock price closed at $3.73. It is down -46.180% in the last 3 months and down -13.260% in the last 12 months.
Caribou Biosciences saw positive EPS revisions and negative EPS revisions in the last 90 days. See Caribou Biosciences's stock price’s past reactions to earnings here.
According to InvestingPro, Caribou Biosciences's Financial Health score is "fair performance".
Check out Caribou Biosciences's recent earnings performance, and Caribou Biosciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar